.svg)
Highlighted Event
Results for the First Quarter 2024
Sales ended at MNOK 133.8, 3.5% above the first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter.
Medistim celebrates a long-standing relationship with the Japanese cardiac surgery community
Dec 2, 2022
This is very much a story of a perfect fit between Norwegian technology and Japanese quality standards. Medistim technology has been able to meet expectations of the quality driven Japanese market. There are few arenas…
Results for the First Quarter 2024
Sales ended at MNOK 133.8, 3.5% above the first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter.
